Psoriasis Drugs: Market Research Report

Date: April 22, 2010
Pages: 568
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PA18DA15860EN
Leaflet:

Download PDF Leaflet

Psoriasis Drugs: Market Research Report
This report analyzes the worldwide markets for Psoriasis Drugs in US$ Million by the following Drug Administration Routes - Systemic Drugs, and Topical Drugs.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Almirall SA, Astellas Pharma US, Inc., Biogen Idec, Inc., Eisai Co.Ltd., Galderma Laboratories, Isis Pharmaceuticals, Inc., Johnson & Johnson Company, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Stiefel Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Vertex Pharmaceuticals, Inc., and Wyeth.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Systemic Drugs
Topical Drugs

II. EXECUTIVE SUMMARY

1.MARKET OVERVIEW

Psoriasis – A Chronic, Widespread Autoimmune Disease

Table 1. World Psoriasis Prevalence (in Million) in Select Countries: 2007-2015 (includes corresponding Graph/Chart)

Psoriasis Poses Risk for Cardiovascular Diseases
Quick Facts About Psoriasis Disease
Quick Facts About Psoriasis Treatment
Global Market Outlook
Psoriasis Drugs Overview
Major Marketed Drugs for Psoriasis Treatment as of 2009
Topical Drugs Overview

Table 2. World Psoriasis Drugs Market – Value Sales of Select Leading Topical Products in US$ Million for 2008 (includes corresponding Graph/Chart)

Foams and Liquid Formulations Gaining Momentum
JAK3 Inhibitors Spell Promising Future for Topical Drugs
Systemic Drugs Overview

Table 3. World Psoriasis Drugs Market – Value Sales of Select Leading Conventional Systemic Products in US$ Million for 2007 (includes corresponding Graph/Chart)

Enbrel – The Market Leader

2.KEY MARKET TRENDS

Market Welcomes New Products, Even As Established Biologic Makes Exit
Conventional Topical Therapies to Remain Mainstay Treatment
Biologics to Witness Robust Growth, Driven by New Product Introductions
Interleukin and TNF-Alpha Inhibitors to Drive Biologics Growth
TNF-Alpha Blockers – The Market Leaders

Table 4. World Psoriasis Drugs Market – Value Sales of Select Leading Biologic Systemic Products in US$ Million for 2008(includes corresponding Graph/Chart)

Interleukin Inhibitors – The Next Big Biologic Class
Non-Prescriptions and Generics Threaten Market Growth
Oral Pipeline Therapies To Take On Biologics
Home Ultraviolet B Therapy to Find Favor with Psoriasis Patients
Paradigm of Psoriasis Treatment
Voclosporin to Edge Out Competitive Products
Apremilast to OUTdo Existing Anti-TNF Products

3.PIPELINE ANALYSIS

The Research Progress in Psoriasis Treatment
Safety Plays Critical Role in Psoriasis Therapy
Major Drug Candidates in Pipeline
Existing and Future Research & Development Approach

Table 5. Psoriasis Drugs Pipeline (2009) - Number of Pipeline Candidates and Clinical Trials (includes corresponding Graph/Chart)

Select Psoriasis Pipeline Candidates for Topical Treatment as of 2009
Select Psoriasis Pipeline Candidates for Oral Treatment as of 2009
Select Psoriasis Pipeline Candidates for Injectable Treatment as of 2009
Other Major Psoriasis Pipeline Candidates in Phase II Clinical Trials as of 2009
NIAID Researchers Identify Potential New Drug Target

4.ALL ABOUT PSORIASIS

What is Psoriasis?
The History of Psoriasis
The History of Psoriasis Treatment
The Risk Factors of Psoriasis
The Cause(s) of Psoriasis
The Aggravating Factors
The Diagnosis of Psoriasis
The Severity of Psoriasis
The Types of Psoriasis
Plaque Psoriasis
Scalp Psoriasis
Nail Psoriasis
Inverse Psoriasis
Guttate Psoriasis
Pustular Psoriasis
Erythrodermic Psoriasis
Psoriatic Arthritis
Others
The Treatment of Psoriasis
The Three-Step Approach to Treatment
Treatment by Disease Severity
Mild Stage Psoriasis Treatment
Moderate Stage Psoriasis Treatment
Severe Stage Psoriasis Treatment
Treatment by Natural Healing
Other Treatment

5.OVERVIEW OF PSORIASIS TREATMENT

Table 6. Therapeutic Modalities for Psoriasis Treatment in Percentage by Disease Stage (includes corresponding Graph/Chart)

Topical Treatment
List of Topical Therapies Available for the Treatment of Mild-to-Moderate Psoriasis
Select Topical Drugs
Clobex (Clobetasol propionate)
Dovonex (calcipotriene)
Olux-E (Clobetasol propionate)
Taclonex/ Dovobet/ Daivobet (calcipotriene/ betamethasone)
Tazorac (Tazarotene)
Vectical (calcitriol)
Systemic Treatment
Select Conventional Systemic Drugs
Methotrexate
Soriatane (acitretin)
Neoral (cyclosporine)
Tegison (etrentinate)
NSAIDs
Biologic Systemic Therapies
List of Approved Biologic Systemic Therapies for Psoriasis
Select Biologic Drugs
Amevive (alefacept)
Enbrel (etanercept)
Humira (adalimumab)
Remicade (infliximab)
Raptiva (efalizumab)
Stelara (ustekinumab)
Phototherapy
UVB Phototherapy
PUVA Phototherapy
Alternative Treatment
Climatotherapy

6.SELECT CLINICAL TRIALS

Isotechnika’s Voclosporin Shows Favorable Results in Phase III Clinical Trial
Provectus Commences New PH-10 Clinical Trials for Psoriasis
Micromet Initiates First Clinical Study for GM-CSF Human Antibody MT203
Welichem Initiates GLP Toxicology Studies for WBI-1001
Anacor Announces Favorable Phase II Trial Results of AN2728
Synvista Initiates Phase II Clinical Trial of Topical SYI-2074
Avontec Announces Positive Results from Phase IIa Clinical Trial of AVT-02 UE
Revotar Announces Favorable Phase I Trial Results of Bimosiamose 5% Cream
Manhattan Completes Enrollment in Phase IIa Clinical Trial of Topical PTH (1-34)
Dermipsor Announces Positive Results from Phase IIb Clinical Trial of DPS-101
BioCryst Completes Phase IIa Study, Announces Promising Results of BCX-4208
Arana Therapeutics Completes Patient Recruitment in Phase II Trial of ART621
Novartis Exploratory Development Study Shows Positive Results for AEB071

7.PRODUCT LAUNCHES/ APPROVALS

Eisai Obtains Japanese Approval for HUMIRA® in Psoriasis Treatment
Janssen-Cilag Launches Stelara® for Plaque Psoriasis
PsoriasisDX Launches Genetic Test for Psoriatic Arthritis
Elorac Launches Zithranol-RR for Plaque Psoriasis
Quinnova Introduces New Treatment for Hyperkeratotic Conditions
Xderma Launches New Ointment for Psoriasis
Promius Pharma Introduces Scytera Foam 2% for Chronic Psoriasis
NeoStrata Launches PSORENT
LEO Pharma to Launch Xamiol®
Glenmark Introduces Dermatology Products
The Kuwait Health Ministry Approves Alalorid for Psoriasis Treatment
CHMP’s Positive Recommendation for Enbrel as Psoriasis Treatment in Children

8.RECENT INDUSTRY ACTIVITY

Cephalon Acquires Arana Therapeutics
GlaxoSmithKline to Acquire Stiefel Laboratories
PhotoMedex Acquires Photo Therapeutics
PPD Acquires Magen BioSciences
Bristol-Myers Squibb Acquires Medarex
Valeant Pharmaceuticals Acquires Dow Pharmaceutical Sciences
Advitech to Acquire Botaneco Specialty Ingredients
Merck Merges with Schering-Plough
Pfzer Acquires Wyeth
Paladin Labs and Isotechnika Pharma Enter into Partnership
Centocor Ortho Biotech Obtains FDA Approval for Golimumab
Centocor Ortho Biotech Obtains FDA Approval for Stelara™
Galderma Receives Approval from FDA for Vectical
LEO Pharma Reacquires Product Licensing Rights from Warner Chilcott
Genentech Withdraws Raptiva from US Market
Prime Pharmaceutical Grants License of Relieva® to Mac Pharma
Dynavax Receives Grant to Support TLR Inhibitors Development from NIAID
Valeant Pharmaceuticals Takes Over DermaTech
Bayer Takes Over Direvo Biotech
Stiefel Laboratories Acquires Barrier Therapeutics
Biotie Therapies Enters in Agreement to Acquire elbion
Galderma Acquires Collagenex
Abbott Obtains FDA Approval for HUMIRA® in Psoriasis Treatment
LEO Pharma and Warner Chilcott Obtain FDA Approval for Taclonex Scalp®
Cytos Joins Hands with Pfizer to Develop Vaccines
Karo Bio and Zylus Cadila Enter into Collaboration
Dermipsor Collaborates with Department of Veterans Affairs and VA Boston Research Institute
GlaxoSmithKline Signs Deal with Dynavax Technologies
RXi Pharmaceuticals Receives Technology License from UMMS
Heilongjiang Tianlong Receives Manufacturing Rights for Four Medicines
Dara BioSciences Raises Funds for Testing of Drugs
Avidas Pharmaceuticals Acquires Rights from Crown Laboratories
LEO Pharma Sets Up LEO Pharma China
Dr Reddy's Established New Subsidiary in the US
Lupin to Outlicense Psoriasis Drugs

9.FOCUS ON SELECT PLAYERS

Abbott Laboratories (US)
Amgen Inc. (US)
Almirall SA (Spain)
Astellas Pharma US, Inc. (US)
Biogen Idec, Inc. (US)
Eisai Co. Ltd. (Japan)
Galderma Laboratories (Switzerland)
Isis Pharmaceuticals, Inc. (US)
Johnson & Johnson Company (US)
LEO Pharma A/S (Denmark)
Merck & Co., Inc. (US)
Novartis AG (Switzerland)
Stiefel Laboratories, Inc. (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Valeant Pharmaceuticals International (US)
Vertex Pharmaceuticals, Inc. (US)
Wyeth (US)

10.GLOBAL MARKET PERSPECTIVE

Analytics by Geographic Region

Table 7. World Recent Past, Current & Future Analysis for Psoriasis Drugs by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 8. World 10-Year Perspective for Psoriasis Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart)

Analytics by Drug Administration Route

Table 9. World Recent Past, Current & Future Analysis for Psoriasis Drugs by Drug Administration Route – Systemic Drugs and Topical Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 10. World 10-Year Perspective for Psoriasis Drugs by Drug Administration Route – Percentage Breakdown of Dollar Sales for Systemic Drugs and Topical Drugs Markets for Years 2006, 2009 and 2015

III. MARKET

1.UNITED STATES

A. MARKET ANALYSIS

Current and Future Analysis
Major Trends
Corticosteroids: Foundation of Mild to Moderate Treatment
Dovonex, Taclonex Remain Standard Topical Treatments
Room for Biologics Penetration As Most Moderate-to- Severe Cases Remain Untreated for Psoriasis
Enbrel to Lead, Despite Losing Share to Humira
Humira Cuts into Enbrel’s Share
Amgen to Redeem 100% North American Rights for Enbrel
J&J's Stelara Unlikely to Take the Market By Storm
FDA Delays Enbrel’s Pediatric Psoriasis Indication
Genentech Withdraws Raptiva, Triggers Safety Concerns
Product Launches
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 11. US Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2.JAPAN

A. MARKET ANALYSIS

Current and Future Analysis
Key Player

B. MARKET ANALYTICS

Table 12. Japanese Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3.EUROPE

A. MARKET ANALYSIS

Current and Future Analysis
Product Launches
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 13. European Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. MARKET ANALYSIS

Current and Future Analysis
Product Launches
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 14. Rest of World Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 75)
Region/CountryPlayers
The United States46
Canada
Japan
Europe
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Skip to top


Ask Your Question

Psoriasis Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: